Department of Cardiological, Thoracic and Vascular Sciences, University of Padua, Via A. Gabelli, 61, 35121 Padua, Italy.
Virchows Arch. 2013 Jul;463(1):1-5. doi: 10.1007/s00428-013-1430-4. Epub 2013 Jun 8.
The Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology created a task force to write a consensus document on when and how endomyocardial biopsy is of help for clinicians in the diagnosis and treatment of patients with heart failure, arrhythmias, and cardiac masses. Endomyocardial biopsy is the gold standard for a definitive diagnosis in disease entities like myocarditis, cardiac allograft rejection, and infiltration/storage myocardial disorders. Use of molecular biology techniques is mandatory to obtain specific information on etiology and pathogenesis and should be carried out as an investigation complementary to histology and immunohistochemistry. Given the complexity of these investigations, endomyocardial biopsy should be performed in or in collaboration with cardiac pathology referral centers, where the whole armamentarium of pathological investigation is available, including molecular techniques. Optimal use of the endomyocardial biopsy requires clinicopathologic correlations.
欧洲心血管病理学协会和心血管病理学学会成立了一个工作组，就何时以及如何通过心内膜心肌活检帮助临床医生诊断和治疗心力衰竭、心律失常和心脏肿块患者撰写一份共识文件。心内膜心肌活检是心肌炎、心脏移植排斥和浸润/储存性心肌疾病等疾病实体明确诊断的金标准。使用分子生物学技术对于获得病因和发病机制的特定信息是强制性的，并且应该作为对组织学和免疫组织化学的补充进行研究。鉴于这些研究的复杂性，心内膜心肌活检应在心脏病理学转诊中心进行或与之合作，在那里可以获得包括分子技术在内的整个病理检查设备。要优化心内膜心肌活检的使用，需要进行临床病理相关性分析。
